Table 4 Summary of studies reporting assessment of ‘other’ (non-EGFR/KRAS) molecular markers
Reference | Patient demographics: | Description of matched pairs | Synchronous/metachronous/metastases, n:n | Molecular marker assessment technique | Mutation frequency,c n/N (%) | Concordance, n/N (%) | |||
|---|---|---|---|---|---|---|---|---|---|
(i) Median age (range), years | N | Tumour sample storage form | Primary | Metastatic: n | Â | ||||
(ii) Gender, n/N (%) male | Histological subtype: n | Time between primary and metastatic tumour sample collection b | |||||||
(iii) Ethnicity [countrya] | Â | ||||||||
(iv) Smoking status, n/N (%) | |||||||||
Assessment of p16 molecular marker | |||||||||
 Marchetti et al. [59] | (i) [Mean] 60 (36–76) | 30 | FFPE | Lung | Lymph node | N/A | Direct sequencing by PCR-SSCP | 6/30 (20) vs 6/30 (20) | (30/30) 100 |
(ii) N/A | N/A | ||||||||
(iii) [Italy] | |||||||||
(iv) N/A | |||||||||
Assessment of somatic alterations | |||||||||
 Vignot et al. [62] | (i) N/A (41–82) | 15 | Frozen | Lung | Locoregional: 7 | 2:13 | Targeted next-generation sequencing assay | [EGFR] | [Somatic mutations] |
(ii) N/A (13/15) | ADC: 8 | CNS: 3 | N/A | 1/32 (3) vs 1/31 (3) | N/A (94) | ||||
(iii) [France] | SSC: 3 | Distant adenopathy: 2 | [GNAS] | [Passenger mutations] | |||||
(iv) Never-smoker: N/A (1/15); ever-smoker: N/A (14/15) | LCC: 2 | Adrenal: 1 | 1/32 (3) vs 1/31 (3) | N/A (63) | |||||
Basaloid carcinoma: 2 | Cutaneous: 1 | [KRAS] | |||||||
Parietal: 1 | 4/32 (13) vs 4/31 (13) | ||||||||
[NOTCH1] | |||||||||
1/32 (3) vs 1/31 (3) | |||||||||
[PIK3CA] | |||||||||
4/32 (13) vs 3/31 (10) | |||||||||
[RB1] | |||||||||
1/32 (3) vs 1/31 (3) | |||||||||
[SMARCA4] | |||||||||
1/32 (3) vs 1/31 (3) | |||||||||
[STK11] | |||||||||
2/32 (38) vs 2/31 (3) | |||||||||
[TP53] | |||||||||
12/32 (41) vs 12/31 (42) | |||||||||
[Large structural alterations] | |||||||||
5/32 (16) vs 5/31 (16) | |||||||||